Cerebral toxoplasmosis (CT) is caused by an opportunistic and ubiquitous protozoan, Toxoplasma gondii. The disease most commonly affects immunocompromised adults, including those with AIDS 1 and the post-BMT population, for whom the infection is almost always fatal. 2 Although slightly more than 100 post-BMT cases of CT have been described, [3] [4] [5] [6] [7] [8] the disease is usually radiologically characterized by multiple necrotic abscesses of the basal ganglia or gray/white matter with variable parenchymal enhancement and hemorrhage. 9 We report the second case of post-BMT CT in 23 years to present radiologically with the phenomenon of notable focal leptomeningeal (LM) enhancement, 10 with diffuse bilateral supratentorial LM enhancement, invasive parenchymal edema and ventriculitis.
The patient was a 19-year-old male who received a second allogeneic haploidentical hematopoietic cell transplant (HCT), with his mother as the donor, for relapsed secondary acute myelogenous leukemia. Before receiving this transplant, he had undergone an autologous cell transplant for relapsed Hodgkin lymphoma, followed by a first allogeneic transplant using a double umbilical cord graft for myelodysplastic syndrome, both performed at other institutions. After the second allogeneic HCT, the patient developed hepatic GvHD and was maintained on tacrolimus and high-dose steroids for immunosuppression. At presentation, he had been taking brincidofovir for 1 month and ambisome for 2 months to treat gastrointestinal infections with adenovirus and Candida glabrata, respectively. He was also receiving Trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis, 160/800 mg administered daily on three consecutive days per week. Before the second allogeneic HCT, the patient and donor tested negative for Toxoplasma gondii (T. gondii) IgG, and the patient tested positive for CMV and EBV IgG. The serostatus for T. gondii of the double cord graft is not known.
On day +161 after his second HCT the patient developed fever, a new-onset complex partial seizure (left arm numbness progressing to left facial twitching with confusion), and clinical signs of septic shock. An electroencephalogram confirmed a right frontoparietal-temporal electrographic seizure. Magnetic resonance imaging (MRI) of the brain on day +162 showed bilateral supratentorial LM enhancement, with surrounding parenchymal edema in the right frontoparietal (FP), right medial temporal (MT) and bilateral subfrontal regions. There was a small (0.6 × 0.4 × 0.8 cm) peripherally enhancing lesion in the right globus pallidus that showed restricted diffusion on diffusion-weighted imaging. Lumbar cerebrospinal fluid (CSF) examination on day +162 revealed mild monocyte pleocytosis, elevated protein, and a normal glucose level. The CSF was negative by PCR for CMV, EBV, HHV6, VZV, HSV types 1 and 2, enterovirus, JC polyoma virus, and cryptococcal latex antigen. The CSF cytologic analysis was also negative for T. gondii (Table 1) .
The patient was started on broad-spectrum antibiotic, antifungal and antiviral therapy but experienced worsening neurologic status on day +166, with dysarthria, left facial droop and left hemiparesis. MRI revealed significant worsening of the diffuse supratentorial bilateral LM enhancement with extension into the lateral ventricles; significantly increased parenchymal edema of the right FP, right MT and bilateral subfrontal regions ( Figure 1a) ; and enlargement of the right basal ganglia ring-enhancing restricted lesion (1 × 1 × 1 cm), consistent with meningoencephalitis or ventriculitis ( Figure 1b ). The neuroradiologic evaluation favored a diagnosis of CT, despite the unusual LM process. A repeat lumbar CSF examination performed after the second MRI scan showed increasing mononuclear pleocytosis and elevated protein (Table 1) . Cytologic evaluation of the CSF identified many tachyzoites within inflammatory cells (monocytes and neutrophils), as well as extracellular organisms (Figure 1c ). Gram and fungal staining of CSF were negative for bacteria and fungi, respectively. Therefore, treatment for T. gondii with sulfadiazine and pyrimethamine with leucovorin was initiated. Both the CSF and peripheral blood repeatedly tested positive for T. gondii by PCR. The CSF also tested negative for the previously mentioned viruses, cryptococcal latex antigen, and GAD65 antibody. The drug administration was continued for 10 weeks, though the sulfadiazine was changed to IV TMP-SMX during week 3 of therapy because of concerns regarding gastrointestinal absorption. After this treatment, the patient experienced recurrent electrographic seizures in the right central, temporal and parietal regions, requiring the administration of multiple anti-epileptic drugs (leviteracetam, lacosamide and phenytoin).
On day +176 post transplant, MRI showed increased parenchymal edema of the right FP lesion, a minimal decrease in the overall LM process, and stable size but reduced edema of the right basal ganglia lesion. The serum tested negative for T. gondii on day +188, whereas the CSF tested positive for T. gondii by PCR on day +189, but no tachyzoites were seen. The patient continued to maintain improved neurologic status, with improved speech and left leg strength and weakness in only his left face and arm. MRI on day +189 showed a considerable improvement in the parenchymal edema of the right FP lesion, further decreased bilateral LM enhancement, and reduced size and edema of the right basal ganglia lesion and temporal lobe (Figure 1d ). On day +196, the peripheral blood tested negative for T. gondii by PCR. On day +200, intermittent seizures prompted a computed tomography brain scan that showed evolutionary changes with calcifications of pre-existing lesions. On day +225, the patient developed respiratory distress, worsening neurologic status, and hepatic and renal dysfunction and was found to have an Aspergillus infection. On day +233, after 10 weeks of treatment for toxoplasmosis, the CSF was still negative for T. gondii by PCR, but MRI revealed new lesions in the right frontal region and left temporal lobe with hemorrhagic stigmata, consistent with central nervous system aspergillosis and a positive test for Aspergillus antigen in the CSF (Table 1) . The patient died from multiple organ failure on day +235. Our patient's clinical and radiologic presentation was atypical for CT, and that diagnosis was not initially considered for several reasons. Most cases of CT in BMT recipients occur~2 months after transplant, with only 15-20% occurring later than day +100, as in our patient. 11 CT usually results from the reactivation of a pretransplant latent infection in seropositive recipients, but this patient was seronegative for T. gondii pretransplant. 11 In addition, TMP-SMX prophylaxis is active against T. gondii (though the patient later admitted noncompliance), and the imaging findings were atypical of CT in post-BMT patients, as diffuse LM enhancement is exceedingly rare in severely immunosuppressed individuals. 9, 10 However, the subcentimetric foci of basal ganglia restricted diffusion in the sea of diffuse supratentorial LM enhancement prompted us to consider a diagnosis of CT. Therefore, we requested a cytologic evaluation of the CSF and molecular testing for T. gondii.
CT was diagnosed based on the presence of tachyzoites in the lumbar CSF, and empirical treatment for T. gondii was begun before the diagnosis was confirmed by molecular microbiological tests of CSF and blood samples. As a result of this early intervention, the patient was eventually able to clear the potentially fatal cerebral toxoplasmosis. To our knowledge, only six adult cases of CT have been described in which the CSF was cytologically positive for tachyzoites. [12] [13] [14] Brogi et al. reviewed 6090 CSF samples over a period of 12 years in their institution but identified only two tachyzoitepositive CSF samples from two different patients (0.03%). 13 However, the total number of CT cases included in that study was unspecified.
Our case also illustrates the diagnostic challenges arising from an unusual imaging phenotype of a relatively well known, common disease (CT) because of the poorly understood interplay between the altered host (the brain of an immunocompromised patient) and the noxious agent (T. gondii). It remains unclear exactly what mechanism predisposes certain patients to develop a misleading, dominantly LM disease rather than the usual scattered parenchymal abscesses. However, it has become very clear that CT in allogeneic HCT recipients follows no typical findings. In addition, in this case, meningitis predominated, and this explains the very rare finding of tachyzoites in CSF mononuclear leukocytes or free in the fluid. Therefore, we suspect that LM presentation of CT, though certainly rare, is under-recognized in the immunocompromised patient population. We hope that our report will raise awareness of this issue. Despite presenting with an overwhelming infection, our patient remained seronegative for the organism. Although it is possible that pretransplant serologic tests for T. gondii were negative because of the patient's immunosuppressed state, the test results were probably truly negative, as the patient tested positive for prior exposure to CMV and EBV. He responded well to CT-directed therapy, and the organism was cleared from his blood and CSF. Unfortunately, the patient subsequently died from organ failure associated with disseminated aspergillosis.
In conclusion, we have described a case of CT in a post-BMT patient with atypical clinical and radiologic presentation and the rare finding of tachyzoites in his CSF. On the basis of our case and others, a diagnosis of CT should be considered in such cases, even in the absence of the radiologic findings that are typical in this clinical setting. PCR testing for T. gondii in the CSF should be considered as a screening test in post-BMT patients presenting with CNS symptomatology and/or typical or atypical features on MRI, together with a cytologic examination of the CSF for the presence of parasites. 
